AEE2: Dr. Jennifer Miller, PhD, Reports Back on the Good Pharma Scorecard 2017
Relentless Health Value™January 09, 201804:236.02 MB

AEE2: Dr. Jennifer Miller, PhD, Reports Back on the Good Pharma Scorecard 2017

Jennifer E. Miller, PhD, is an Assistant Professor at the NYU School of Medicine and President of the nonprofit, Bioethics International. She is also the Creator of the Good Pharma Scorecard, an index that ranks all new drugs and large pharmaceutical companies on their ethics and public health performance to help recognize good practices in companies, improve trustworthiness, and incentivize change where needed.  Prior to joining NYU, Dr. Miller was based at Harvard University.

Dr. Miller currently serves on NYU’s Pharmacy and Therapeutics Committee and Stem Cell Research Oversight IRB, as well as
the J&J-NYU Compassionate-Use Advisory Committee (monitor). Previously, she served on the Center for Disease Control and Prevention’s (CDC) Task Force for Pediatric Emergency Mass Critical Care, the American Medical Association’s (AMA) Advanced Disaster Life Support Education Consortium, as a consultant to the United Nations Economic and Social Council, and on the PCORI-NIH Collaboratory.

A prolific writer, Dr. Miller has authored over 35 articles in publications including Nature Medicine and Health Affairs. She was a Fox News pundit from 2009 to 2012 and remains a news commentator, frequently featured on CBS news, Wall Street Journal, Washington Post, Bloomberg News, Forbes, and NPR.

Dr. Miller’s current work explores the ethics and governance of new drugs that are researched, developed, marketed, priced, and made accessible to patients globally. She also specializes in the ethics of data sharing.

00:00 EP148: Jennifer E. Miller, PhD, Bioethics International and Creator of the Good Pharma Scorecard.
01:00 The Good Pharma Scorecard rankings for 2017.
01:40 Two 100% transparent pharma companies.
02:20 Two stats that prove that Pharma companies are improving.
03:00 Industry improvements on patient trials.
03:25 Ninety-six percent of all patient trials are available to the public.
03:45 Where there wasn’t a significant improvement in disclosure in pharma.